Genexine

GX-188E,

First-in-class DNA vaccine
Paradigm shifting novel pipeline

for saving lives of patients with HPV related cancers
GX-I7,

The only long-acting interleukin-7 drug
Amplifying number of T-cells and unlimited potential

to be developed in combination with global immuno-oncology drugs
Bio-better drugs for
driven by
proprietary Long-acting hyFc® platform technology
for rare diseases treatment
GX-E4, the long-acting anemia treatment & GX-H9, growth hormone deficiency treatment are in phase 3 clinical trials.
Saving lives
by innovative biologics
Brings healthier, better lives,
we’re pursuing new ways to address patients’ most serious health issues
Sharing values
for better future
Genexine believes responsible and Innovative minds
brings better lives of healthy people and a healthy society of our future
sroll

Saving lives
through innovation

Saving lives
through innovation

OUR SCIENCE

Genexine’s immune-oncology experts
with extensive experience in
academic research focuses on
the research and development
of novel drugs.

Investor

Current Price
7,070
Change
▼ 120
Volume
97,289
Change Percentage
-1.67%